ロード中...
Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial
BACKGROUND: Long-acting injectable cabotegravir (CAB LA) is a novel integrase inhibitor in advanced clinical development for HIV treatment and HIV prevention. We investigated the terminal pharmacokinetics and safety of CAB LA after final injection as part of a Phase 2 study. METHODS: We performed a...
保存先:
| 出版年: | Lancet HIV |
|---|---|
| 主要な著者: | , , , , , , , , , , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2020
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7859863/ https://ncbi.nlm.nih.gov/pubmed/32497491 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2352-3018(20)30106-5 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|